These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28163544)

  • 1. Lifitegrast: A novel drug for treatment of dry eye disease.
    Abidi A; Shukla P; Ahmad A
    J Pharmacol Pharmacother; 2016; 7(4):194-198. PubMed ID: 28163544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease.
    Semba CP; Gadek TR
    Clin Ophthalmol; 2016; 10():1083-94. PubMed ID: 27354762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease.
    Perez VL; Pflugfelder SC; Zhang S; Shojaei A; Haque R
    Ocul Surf; 2016 Apr; 14(2):207-15. PubMed ID: 26807723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis.
    Li JX; Tsai YY; Lai CT; Li YL; Wu YH; Chiang CC
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [TOPICAL ANTI-INFLAMMATORY AGENTS FOR DRY EYE DISEASE].
    Erdinest N; Solomon A
    Harefuah; 2019 Feb; 158(2):130-135. PubMed ID: 30779493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lifitegrast for the treatment of dry eye disease in adults.
    Donnenfeld ED; Perry HD; Nattis AS; Rosenberg ED
    Expert Opin Pharmacother; 2017 Oct; 18(14):1517-1524. PubMed ID: 28841079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease.
    Paton DM
    Drugs Today (Barc); 2016 Sep; 52(9):485-493. PubMed ID: 27883115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy.
    Godin MR; Gupta PK
    Clin Ophthalmol; 2017; 11():951-957. PubMed ID: 28579745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease.
    Pflugfelder SC; Stern M; Zhang S; Shojaei A
    J Ocul Pharmacol Ther; 2017; 33(1):5-12. PubMed ID: 27906544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quintessence of currently approved and upcoming treatments for dry eye disease.
    Patil S; Sawale G; Ghuge S; Sathaye S
    Graefes Arch Clin Exp Ophthalmol; 2024 Aug; ():. PubMed ID: 39215848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials.
    Holland EJ; Whitley WO; Sall K; Lane SS; Raychaudhuri A; Zhang SY; Shojaei A
    Curr Med Res Opin; 2016 Oct; 32(10):1759-1765. PubMed ID: 27388660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
    Keating GM
    Drugs; 2017 Feb; 77(2):201-208. PubMed ID: 28058622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry eye syndrome: developments and lifitegrast in perspective.
    Lollett IV; Galor A
    Clin Ophthalmol; 2018; 12():125-139. PubMed ID: 29391773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review.
    Atallah RT; Castanos MV; Najac R; Donnenfeld E
    Clin Ophthalmol; 2019; 13():1033-1037. PubMed ID: 31354236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra
    Hovanesian JA; Nichols KK; Jackson M; Katz J; Chan A; Glassberg MB; Sloesen B; Korves C; Nguyen C; Syntosi A
    Clin Ophthalmol; 2021; 15():1041-1054. PubMed ID: 33727786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of Artificial Tears and Use of Adjunctive Dry Eye Therapies After Lifitegrast Treatment: Evidence from Clinical and Real-World Studies.
    Nichols KK; Donnenfeld ED; Lau C; Syntosi A; Karpecki P; Hovanesian JA
    Clin Ophthalmol; 2022; 16():909-916. PubMed ID: 35368241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues.
    Du G; Du W; An Y; Wang M; Hao F; Tong X; Gong Q; He X; Jiang H; He W; Zheng M; Zhang D
    Med Chem Res; 2022; 31(4):555-579. PubMed ID: 35194364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program.
    Chan CC; Prokopich CL
    J Pharm Pharm Sci; 2019; 22(1):49-56. PubMed ID: 30636670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.